NEW YORK; Apr. 22, 2015 – Accenture (NYSE: ACN) has expanded the Accenture Life Sciences Cloud for Research and Development (R&D) powered by Oracle with the addition of enhanced clinical data management capabilities. This enables life sciences companies to generate high-quality, reliable and statistically sound data from clinical trials to reduce the time, effort and cost needed to take drugs from development to market.
This latest version of the Accenture Life Sciences Cloud for R&D offers the Oracle Health Sciences Data Management Workbench (DMW), which includes prebuilt integrations to the Oracle Health Sciences InForm, an electronic data capture (EDC) solution to create an end-to-end clinical data collection and management platform.
With the addition of the Oracle Health Sciences DMW, the Accenture Life Sciences Cloud for R&D automates the time-consuming and resource-intensive manual processes required to load, transform and clean trial data. Trial sponsors and contract research organizations will now be able to increase the speed and accuracy of data collection, integration and analysis; achieve greater efficiency of clinical workflow and query management; and accelerate stakeholders’ access to data across the trial lifecycle from source to submission.
The Oracle Health Sciences DMW provides the Accenture Life Sciences Cloud for R&D with several key benefits, including:
Additionally, the Oracle Health Sciences DMW in the Accenture Life Sciences Cloud for R&D is pre-integrated with the Oracle Health Sciences InForm EDC platform. The latest release of InForm, version 6.1, enables fully integrated capabilities including coding and IRT, rapid and reliable trial builds, and one-click, self-service deployment, including mid-study changes. As a result, life sciences organizations gain a seamless flow of data, from electronic data capture to data management to analysis.
“Being able to take advantage of new technologies for clinical data management in combination with Oracle InForm is a key factor to helping our clients bring life-improving medicines to patients faster,” said Kevin Julian, managing director of Accelerated R&D Services, Accenture Life Sciences. “This latest version of Accenture Life Sciences Cloud for R&D harnesses the highly differentiated capabilities of a pre-integrated end-to-end clinical R&D platform based on leading technology from Oracle.”
The combined solution from Accenture – a Diamond-level member of Oracle PartnerNetwork - and Oracle bring together Oracle’s experience in developing and hosting mission-critical clinical data warehousing and analytics applications for life sciences with Accenture’s proven implementation capabilities to deliver service-based solutions.
“As the industry’s only true end-to-end data management solution in a single environment, Oracle Health Sciences Data Management Workbench accelerates the speed and accuracy of clinical data integration, reconciliation, aggregation, and analysis by reducing time -consuming manual processes required to load, transform, and clean trial data. Accenture’s Life Sciences Cloud for R&D with Data Management Workbench is changing the way technology is developed and delivered across the life sciences industry, helping life sciences organizations provide life-improving therapies faster and at a lower cost,” said Steve Rosenberg, general manager of Oracle’s Health Sciences Global Business Unit. “We at Oracle are proud that our industry-leading cloud solutions are at the heart of this leading capability.”
As previously announced in October, the Life Sciences Cloud Coalition is a ground-breaking initiative, in parallel with the Accenture Life Sciences Cloud for R&D platform, to build an assembly of like-minded leaders, collaborating for a healthier industry in non-competitive areas. The focus of the coalition is on driving innovation in the Accenture Life Sciences Cloud to digitally enable the R&D function, speed the drug development process while improving quality and cost for the industry. Members of the Life Sciences Cloud Coalition include Accenture, Oracle, Eisai, Pfizer, Merck, and other leading pharmaceutical companies.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.